News

Eylea, also known VEGF Trap-Eye, is a recombinant fusion protein, consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of

Following the authorization, Eviplera will be made commercially available in all 27 countries of the European Union (EU). Eviplera combines Gilead’s Truvada, a fixed-dose combination of the two

The institute will transform basic discoveries into new drugs and complementary diagnostics for cancer patients besides improving translational and clinical research, newswise.com reported. MD Anderson president Ronald DePinho

The initiative is believed to help small and large companies to lease the facilities needed to produce FDA regulated material. According to the company, this program will allow

Under the terms of the agreement, the Japanese agency will support State Pharmaceutical Corporation of Sri Lanka in the production of drugs locally, news.lk reported. Currently, 50 varieties

Blinatumomab is a next-generation monoclonal antibody designed to direct the body’s cell destroying T-cells against CD19, a protein expressed on the surface of B-cell derived acute lymphoblastic leukemias

OBI-1, an intravenous recombinant porcine factor VIII (FVIII) product which shows low cross reactivity to antihuman FVIII antibodies, is a replacement therapy, activating the intrinsic hemostatic pathway. The

According to the company, the facility is expected to support around $1.0bn in revenue for the company’s enzyme replacement therapy portfolio including complex glycoprotein products produced by mammalian

Rasitrio acts by targeting renin for optimal control of the renin angiotensin aldosterone system (RAAS), which is a key regulator of high blood pressure. The approval is based